Clinical & Diagnostic

Andelyn Biosciences Selected by UMass Chan Medical School to Manufacture AAV9-CSA Vector for Cockayne Syndrome Treatment

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selecte...

 July 11, 2024 | News

Surfix Diagnostics, NKI, and CRCbioscreen Collaborate to Enhance Colorectal Cancer Screening

Surfix Diagnostics alongside the Netherlands Cancer Institute (NKI) and CRCbioscreen, announce a collaboration aimed at enhancing colorectal cancer (CRC) s...

 July 10, 2024 | News

Immorna Biotherapeutics to Launch Phase 1/2 Study of Novel mRNA Therapeutic for Cancer

Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics a...

 July 09, 2024 | News

Hinova Pharmaceuticals Secures FDA Fast Track Designation for HP518 in Treating AR+ Triple-Negative Breast Cancer

Hinova Pharmaceuticals  a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food an...

 July 08, 2024 | News

XPOVIO® Secures NMPA Approval for Treatment of R/R DLBCL in China, Expanding Its Indications

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...

 July 08, 2024 | News

Aptamer Group and AstraZeneca Collaborate to Advance Targeted siRNA Delivery for Fibrotic Liver Cells

  Aptamer Group , the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce a new agreem...

 July 05, 2024 | News

APPIS Innovator Program 2024 Winners Announced

    The APPIS Innovator Program 2024 has concluded with an impressive showcase of 49 entries from 21 countries, each addressing critical barrie...

 July 04, 2024 | News

Lilly Forms Strategic Partnership with Radionetics for GPCR-Targeted Radiopharmaceuticals

Provides Lilly access to Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals Radionetics to receive $140 million upfront p...

 July 02, 2024 | News

Bayer and Rad AI Collaborate to Enhance Radiology Operations with Advanced AI Solutions

As experts from around the globe gather at the annual Society for Informatics in Medicine (SIIM) conference, Bayer and Rad AI are announcing a collaboratio...

 June 28, 2024 | News

South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...

 June 27, 2024 | News

Hyundai Bioscience Develops Innovative Niclosamide-Based Multi-Treatment Drug for Mosquito-Borne Viral Infections

Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus...

 June 26, 2024 | News

Thermo Fisher Scientific Introduces Innovative KingFisher™ PlasmidPro System for Plasmid DNA Purification

Thermo Scientific™ KingFisher™ PlasmidPro prepares high purity plasmid DNA in approximately 75 minutes, half the traditional process time and w...

 June 26, 2024 | News

FDA Approves iRegene's NouvNeu001, Marking Milestone in Parkinson's Disease Treatment

U.S. Food and Drug Administration (FDA) approved the IND application for NouvNeu001, a cell therapy product from iRegene therapeutics targeting Parkinson's...

 June 25, 2024 | News

EU Approves HUTCHMED's FRUZAQLA® for Previously Treated Metastatic Colorectal Cancer

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...

 June 24, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close